Evidence map›Paper›PMID 41467943›Full record

SynthesisInternational journal of colorectal disease2025

Safety and efficacy of IL-23 inhibitors in patients with moderate to severe ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.

Hamza Muhammad Amin, Sundas Hasan, Reem Abukhater, Rachel Lilley, Arif Atique, Maheen Sattar Shoaib, Qutaiba Albustanji, Humza Sadique, Saad Muhammad Khalid, Ali Hasan and 6 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hamza Muhammad Amin *Department of Internal Medicine, South Tees Hospital, Middlesbrough, UK.
Sundas Hasan *Department of Gastroenterology, University Hospitals of Leicester, Leicester, UK.
Reem AbukhaterDepartment of Medicine, RAKMHSU, Ras Al Khaimah, United Arab Emirates.
Rachel LilleySouth Tyneside and Sunderland Foundation Trust, Sunderland, UK.
Arif AtiqueDepartment of Gastroenterology, South Warwickshire University NHS Foundation Trust, West Midlands, UK.
Maheen Sattar ShoaibDepartment of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
Qutaiba AlbustanjiDepartment of Internal Medicine, Specialty Hospital, Amman, Jordan.
Humza SadiqueDepartment of Medicine, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.
Saad Muhammad KhalidDepartment of Gastroenterology, The Shrewsbury and Telford Hospital NHS Trust, West Midlands, UK.
Ali HasanDepartment of Medicine, Imperial College London, London, UK. ali.hasan21@imperial.ac.uk.
Salman MajeedDepartment of Internal Medicine, University Hospitals of Leicester, Leicester, UK.
Muhammad Aamir ShahzadDepartment of Gastroenterology, Northampton General Hospital NHS Trust, Northampton, UK.
Maryam ShahzadDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Mushood AhmedDepartment of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Raheel AhmedNational Heart & Lung Institute, Imperial College London, London, UK.
Syed Anjum GardeziDepartment of Gastroenterology, John's Hopkins HealthCare Aramco, Dhahran, Eastern Province, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveTargeting the interleukin-23 (IL-23) pathway is an emerging therapeutic strategy for moderate to severe ulcerative colitis (UC). This systematic review and meta-analysis evaluated the efficacy and safety of IL-23 inhibitors for induction and maintenance therapy in UC.

methodsA systematic search of PubMed, Cochrane, and Google Scholar was conducted up to May 2025 to identify randomized controlled trials (RCTs) of IL-23 inhibitors (mirikizumab, risankizumab, guselkumab) in UC. Data were analyzed using Review Manager (RevMan 5.4) with a random-effects model.

resultsSeven RCTs (four induction, three maintenance) including 4203 patients were analyzed. IL-23 inhibitors significantly increased clinical remission during both induction (RR 1.52) and maintenance (RR 1.62). Rates of histo-endoscopic healing were also higher with IL-23 blockade in both induction (RR 2.53) and maintenance (RR 1.81). Importantly, IL-23 inhibitors were associated with a reduced risk of serious adverse events during induction (RR 0.39), with no significant difference observed during maintenance (RR 0.68). Other outcomes, including clinical response and corticosteroid-free remission, also consistently favored IL-23 blockade.

conclusionIL-23 inhibitors provide significant improvements in clinical remission and mucosal healing, with a favorable safety profile, particularly during induction therapy in moderate to severe UC.

Indexed as

Colitis, UlcerativeInterleukin-23Randomized Controlled Trials as TopicAntibodies, Monoclonal, HumanizedHumansPublication BiasRemission InductionSeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, HumanizedInterleukin-23IL-23 inhibitorsMeta-analysisUlcerative colitis

Identifiers

PMID41467943
PMCPMC12764650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.